Deerfield Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Deerfield Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-126,895	Closed	-$7.53M	–	108
2020 Q1	$7.53M	Hold	126,895	–	–	0.24%	78
2019 Q4	$8.77M	Hold	126,895	–	–	0.28%	61
2019 Q3	$13.2M	Hold	126,895	–	–	0.54%	55
2019 Q2	$11.8M	Hold	126,895	–	–	0.42%	67
2019 Q1	$11.6M	Hold	126,895	–	–	0.44%	57
2018 Q4	$7.07M	Hold	126,895	–	–	0.28%	71
2018 Q3	$15.1M	Hold	126,895	–	–	0.54%	56
2018 Q2	$13M	Hold	126,895	–	–	0.46%	74
2018 Q1	$16.5M	Hold	126,895	–	–	0.57%	62
2017 Q4	$12.3M	Hold	126,895	–	–	0.49%	60
2017 Q3	$18.7M	Hold	126,895	–	–	0.84%	37
2017 Q2	$20.4M	Sell	126,895 -34,619	-21%	-$5.44M	1.09%	28
2017 Q1	$25.7M	Sell	161,514 -19,764	-11%	-$2.41M	0.99%	38
2016 Q4	$22M	Hold	181,278	–	–	0.91%	36
2016 Q3	$25.1M	Sell	181,278 -28,244	-13%	-$3.58M	1.17%	28
2016 Q2	$38M	Buy	+209,522	New	+$38M	1.49%	23

Other funds holding SYRS

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management's SYRS Position: Q2 2020 in Review

Deerfield Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2020, closing a stake of 126,895 shares — an estimated $7.53M sold.

Deerfield Management first reported a position in SYRS in Q2 2016 and held it in 16 quarters. The position peaked at $38M in Q2 2016. 79 funds tracked by Wall St. Rank hold SYRS as of Q2 2020.

Deerfield Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Deerfield Management sold 126,895 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $7.53M.
Deerfield Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2016 and held it in 16 quarters.
Deerfield Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $38M in Q2 2016.
79 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Deerfield Management's 13F filing for Q2 2020, filed 14 Aug 2020.